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Abstract
Background: Traumatic brain injury (TBI) is a main cause of severe prolonged disability of young patients. Hospital
acquired pneumonia (HAP) add to the morbidity and mortality of traumatic brain-injured patients. In one study,
hydrocortisone for treatment of traumatic-induced corticosteroid insufficiency (CI) in multiple injured patients has
prevented HAP, particularly in the sub-group of patients with severe TBI. Fludrocortisone is recommended in severe
brain-injured patients suffering from acute subarachnoid hemorrhage. Whether an association of hydrocortisone
with fludrocortisone protects from HAP and improves neurological recovery is uncertain. The aim of the current
study is to compare corticotherapy to placebo for TBI patients with CI.
Methods: The CORTI-TC (Corticotherapy in traumatic brain-injured patients) trial is a multicenter, randomized,
placebo controlled, double-blind, two-arms study. Three hundred and seventy six patients hospitalized in Intensive
Care Unit with a severe traumatic brain injury (Glasgow Coma Scale ≤ 8) are randomized in the first 24 hours
following trauma to hydrocortisone (200 mg.day
-1 for 7 days, 100 mg on days 8-9 and 50 mg on day-10) with
fludrocortisone (50 μg for 10 days) or double placebo. The treatment is stopped if patients have an appropriate
adrenal response. The primary endpoint is HAP on day-28. The endpoint of the ancillary study is the neurological
status on 6 and 12 months.
Discussion: The CORTI-TC trial is the first randomized controlled trial powered to investigate whether
hydrocortisone with fludrocortisone in TBI patients with CI prevent HAP and improve long term recovery.
Trial registration: NCT01093261
Keywords: Trauma, Traumatic brain injury, corticosteroid insufficiency, glucocorticoid, mineralocorticoid, pneumo-
nia, nosocomial infection, intensive care unit
Background
Traumatic brain injury (TBI) is a leading cause of pro-
longed disability in young patients. The rate of hospital
acquired pneumonia (HAP) varies from 30 to 50% [1-3].
Post traumatic HAP increases the risk of intracranial
hypertension [4], prolongs duration of mechanical venti-
lation and Intensive Care Unit (ICU) length of stay [5,6]
and may increase the rate of death [7]. Prevention of
one episode of HAP may save 20,000$ [8].
Critical Illness Related Corticosteroid Insufficiency
(CIRCI) reaches up to 50 to 70% of trauma patients
[9-11]. CIRCI increases systemic inflammation and vaso-
pressive requirement [9,12]. Hydrocortisone decreases
rate of HAP and duration of mechanical ventilation in
multiple trauma patients with CIRCI [10]. In a sub-
group analysis of the HYPOLYTE trial, hydrocortisone
appears particularly efficient in multiple trauma patients
with TBI [10]. Fludrocortisone was proposed in associa-
tion with hydrocortisone for the treatment of CIRCI in
septic patients [13] and is recommended in BI patients
with spontaneous subarachnoid hemorrhage who experi-
ence hyponatremia [14]. No data regarding fludrocorti-
sone use in TBI patients are available to date.
* Correspondence: karim.asehnoune@chu-nantes.fr; karim.asehnoune@chu-
nantes.fr
1Centre Hospitalier Universitaire de Nantes, Service d’anesthésie réanimation
chirurgicale, Hôtel Dieu-HME, Nantes, France
2Intensive care Unit, Hotel Dieu, (Place Ricordeau), Nantes (44093), France
Full list of author information is available at the end of the article
Asehnoune et al. Trials 2011, 12:228
http://www.trialsjournal.com/content/12/1/228 TRIALS
© 2011 Asehnoune; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.The CORTI-TC study aims to test the effects of pro-
longed low dose of hydrocortisone together with fludro-
cortisone for prevention of HAP and long term
neurological and psychological recovery in patients with
severe TBI.
Methods and Design
Objectives and design
The Corticotherapy in traumatic brain-injured patients
(CORTI-TC) study is a nationwide multicenter, rando-
mized, double blind, placebo controlled trial. The Insti-
tutional Review Board of Tours (France) approved the
study protocol. The CORTI-TC is conducted in accor-
dance with the declaration of Helsinki and was regis-
tered on March 23 2010 at http://clinicaltrial.gov/ with
trial registration NCT01093261.
CONSORT diagram
Figure 1 shows the CONSORT diagram of the CORTI-
TC trial.
Study population
Investigators screen consecutive severe TBI patients
defined as the association of a Coma Glasgow Scale ≤ 8
together with a traumatic anomaly on tomodensitome-
try. Inclusions criteria are: severe traumatic BI, in the
first 24 hours following trauma, age between 15 and 65
years and informed consent from a next-of-kin. Exclu-
sions criteria are: associated tetraplegia, previous immu-
nosuppression, corticotherapy in the previous 6 months,
antibiotherapy for active sepsis at the time of inclusion.
Randomization
Patients eligible for inclusion should be randomized, and
the study treatment is started within the first 24 hours.
Patients are randomized in a 1:1 ratio in fixed blocks of
12 and stratified according to the center and MGAP
score [15] by a computerized number generator list pro-
vided by a statistician not involved in the determination
of eligibility or in the assessment of outcomes. All
assignments are made through a dedicated, pass-word
protected, SSL-encrypted website. Randomized patients
are given a number corresponding to a «Corti-TC treat-
ment pack» that contains: 20 × 100 mg vial of hydrocor-
tisone or placebo, 10 pills of 50 μg of fludrocortisone or
placebo and a sheet for schedule administration.
Study protocol
Immediately after randomization, and before study drug
administration, a short corticotropin test is performed
(basal cortisolemia followed by 0.25 mg of synacthene
®
and cortisolemia on the 60
th min.). Patients are rando-
mized to intravenous infusion of hydrocortisone (200 mg.
day
-1 for 7 days, 100 mg on days -8 and -9, 50 mg on day-
10) with enteral administration of fludrocortisone (50 μg.
day
-1 for ten days) or to placebo. After receiving the results
of the short corticotropin test (usually in the first 48 hours
following inclusion), the treatment is stopped if patients
have an adapted corticosteroid function.
Protocol drop-out
Clinicians are allowed to use corticotherapy at any time
point if there is an absolute adrenal insufficiency (basal
cortisolemia below 30 μg.dl
-1), a septic shock or an Acute
Respiratory Distress Syndrome. Enteral administration of
the study drug (Fludrocortisone or Placebo) can be
stopped in case of hypernatremia (>155 mmol.l
-1) asso-
ciated with a low natriuresis (< 20 mmol.l
-1). The com-
plete follow up is always performed and patients are kept
in the statistical analysis.
Biological assessment
Immediately before starting the treatment, but at least 8
hours after a bolus injection of etomidate [10,13], a
short corticotropin test is performed: cortisolemia before
and 60 minutes after an intravenous bolus of 0.25 mg of
corticotropin (Novartis
®, Rueil-Malmaison, France). A
second short corticotropin test is performed on day-11
o r- 1 2 .A tt h es a m et i m ep o i n t s ,p l a s m aa n ds e r u ma r e
frozen at -80°C for ancillary studies.
Study end points
Primary endpoint is the occurrence of HAP within 28
days of randomization. Pneumonia is considered when
at least 2 signs (body temperature > 38°C; leukocytosis
>12 000/mL, or leukopenia <4000/mL; purulent pul-
monary secretions) associated with the appearance of a
new infiltrate are present or when changes occur in an
existing infiltrate on chest x-ray. The diagnosis needs to
be confirmed by a respiratory tract sample using a
quantitative culture with a predefined positive threshold
of 10
4 colony-forming units per milliliter (CFU/mL) for
a bronchoalveolar lavage or non bronchoscopic sample,
of 10
3 CFU/mL for a protected specimen brush and of
10
6 CFU/mL for a tracheal sample. Hospital-acquired
pneumonia is defined as pneumonia that occurs 48
hours after admission that had not been incubating at
the time of admission.
The secondary outcomes are duration of mechanical
ventilation and length of ICU stay, antibiotic free days,
rate of death, other infections, organ failures, and dura-
tion of vasopressor support on day 28 and in ICU.
Safety is assessed by recording adverse events.
An ancillary study will assess the mortality, the long
term neurological and psychological recovery on the -6
th
and -12
th month.
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The following variables are collected: demographics,
Apache 2, MGAP score [15], injury severity score and
abbreviated injury score, fluid infusions, vasopressors,
antibiotherapy, etomidate use, surgery, intracranial pres-
sure, infections, organ failures, natremia, length of venti-
latory support, and ICU hospitalisation and death in
ICU and at day 28 are recorded. In ICU, clinical assess-
ments are performed at least twice a day. Clinical eva-
luation for diagnosis of pneumonia are performed twice
a day in the ICU. A chest x-ray is performed as soon as
pneumonia is suspected after clinical examination. A
respiratory tract sample is collected for bacteriological
analysis before any modification of antibiotic therapy.
Patients or relatives are contacted on -6 and -12 month
for evaluation of neurological recovery (GOS, Kartz
index), of quality of life, of depression disorder (HAD
scale, SF-36 and I.E S-R scores) and of mortality.
Statistical consideration
The required sample size is calculated from results of
the HYPOLYTE study [10]. The power calculation is
performed for comparison between the hydrocortisone
and placebo groups in patients with corticosteroid insuf-
ficiency. The sample size needed to detect an absolute
decrease in pneumonia incidence of 20% is 121 patients
in each group, assuming a rate of 70% in the placebo
group, in a 2-sided test performed with a statistical
power of 90% and an a risk of 5%. Assuming a rate of
75% of corticosteroid insufficiency [10], 326 patients
ICU: Intensive Care Units  
Figure 1 CONSORT diagram of the CORTI-TC trial
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patients with normal corticosteroid function who are
untreated) are needed. Two a priori interim analyses
using the O’Brien and Fleming method for a risk spend-
ing are planned respectively after the inclusion of 110
and 220 patients.
An ITT and a mITT analysis will be performed.
Because the patients with adapted corticosteroid func-
tion are left untreated (whent h ec o s y n t r o p i nt e s ts h o w
no corticosteroid insufficiency), a modified intention-to-
treat (mITT) analysis that includes only the patients
with corticosteroid insufficiency is planned.
Statistical analysis
P r i m a r yo u t c o m ei st h eo c c u r r e n c eo fH A Pw i t h i nt h e
first 28 days after randomization. The primary analysis
will use a Cox multivariate proportional hazards
model that includes 2 predefined covariable: MGAP
[15] and Coma Glasgow Score. We will also perform
complementary sensitivity analyses with an adjuste-
ment on etomidate use. Corresponding hazard ratios
(HRs) along with their 95% confidence intervals (CIs)
will be reported. The crude percentages and the
Kaplan-Meier estimators will also be presented.
Cumulative incidence will also be estimated for the
primary outcome by treating deaths as competing
r i s k s .T h eF i n ea n dG r a ym o d e l[ 1 6 ]w i l lb eu s e d .I fa
difference is confirmed for the primary endpoint, sub-
group analysis for multiple trauma (presence or
absence), hyporeactivity to adrenocorticotrophic hor-
mone (presence or absence), early treatment adminis-
tration (<18 hours after trauma or >18 hours) will be
performed. In order to control the family wise error
rate, a stepwise hierarchal testing procedure will be
used for subgroup analyses.
Normally distributed variables will be expressed as
mean and standard deviation; non-normally distributed
variables will be expressed as median and inter quartile
ranges. Categorical variables will be expressed as num-
bers and percentage, as well as the absolute difference
(95% CI). Linear or logistic regressions will be used as
appropriate for the secondary endpoints.
Study Organization
The financial support are provided by the Société Fran-
çaise d’Anesthésie Réanimation (SFAR). Study promo-
tion is performed by Nantes University Hospital.
The independent Data and Safety Monitoring Board
(DSMB) look over the ethics in accordance with the
Declaration of Helsinki, monitors patient safety and
reviews safety issues as the study progresses. Serious
adverses events and unexpected related or possibly
related serious events are reported blinded to the DSMB
within respectively 24 hours or 7 days.
Patients are treated in level I trauma centers according
to the Advanced Trauma Life Support principles.
Discussion
The Corti-TC trial is the second randomized controlled
study powered to investigate prolonged low dose of cor-
ticosteroid therapy in severe trauma patients, and the
first one focusing on severe TBI patients.
Cortisol production is necessary for normal host
defence against infection. Hydrocortisone dampens
inflammation while preserving innate immunity [17] and
improves the recovery from severe community-acquired
pneumonia [18]. Trauma-induced inflammation, which
is exacerbated in cases of corticosteroid insufficiency
[19], leads to infection [12]. In the HYPOLYTE study
[10], low dose of hydrocortisone decreased rate of HAP
in intubated trauma patients with corticosteroid
insufficiency.
The primary outcome of this trial is HAP, that could
be considered as a shortcoming since the prevention of
HAP does not always improves outcomes of ICU
patients [20]. Infections are the most frequent cause of
complications in severely injured patients [21]. The inci-
dence of pneumonia is particularly high in trauma
patients, reaching up to 50% [2-4]. Post-trauma pneu-
monia is responsible for an increased morbidity (dura-
tion of mechanical ventilation and ICU hospitalization)
[5,6], and the average cost for each pneumonia episode
is high [8]. In the HYPOLYTE study, together with a
decreased in rate of HAP, hydrocortisone decreased
both duration of mechanical ventilation and ICU length
of stay. Thus, we considered that the most relevant end-
point would be HAP.
Criteria for HAP diagnosis has not been studied in
trauma patients treated with hydrocortisone and theore-
tically the study treatment may decrease the ability of
clinician’s to diagnose HAP. For community-acquired
pneumonia, the body temperature of patients treated
with a high dose of glucocorticoid was slightly decreased
(by less than 0.5°C) as compared to placebo-treated
patients [22], but to our knowledge, the effects of stress
dose hydrocortisone (if any) are unknown in trauma
patients. Also, in case of CIRCI hydrocortisone should
restore the ability to develop fever, and patients without
CIRCI (left untreated) should not present any dysregula-
tion in thermoregulation abilities. Finally, we assumed
that hydrocortisone with fludrocortisone will not biased
HAP diagnosis.
Major modifiable risk factors for HAP as described by
the American thoracic Society [23] are prospectively col-
lected: oropharyngeal decontamination, proclive (>30°),
stomach ulcer prevention, insulinotherapy, tracheostomy
and protocol for sedation. All these factors can not be
standardized in the protocol. Sedation is a cornerstone
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was not practical to perform either daily spontaneous
breathing trials or daily liberation from sedation in a
population of traumatic brain injury patients. Concern-
ing tracheostomy, prevention of HAP by performing tra-
cheostomy early is still debated. In a recent study, the
incidence of HAP was similar in patients with early ver-
sus late tracheostomy [25]. None of the participating
ICUs usually perform early tracheostomy or “daily spon-
taneous breathing” in TBI patients during the study per-
iod. Regarding insulinotherapy, tight glycemia control is
a highly debated topic for ICU patients and is associated
either with beneficial [26] or deleterious effects [27]. A
tight glycemic control was not associated with any survi-
val improvement of septic patients treated with hydro-
cortisone [28]. Proclive and oropharyngeal
decontamination are commonly used in participating
ICUs. Finally, a controlled double-blind randomized
design may ensure the comparability of groups for the
majority of interventions other than hydrocortisone
infusion.
In this study, we use a placebo in a population of
CIRCI patients. This point do not raise an ethical issue
as the recommendations for the diagnosis and treatment
of CIRCI recently published by the American College of
Critical Care Medicine [29] state that: first, given the
lack of data, treatment of CIRCI is not recommended in
other population than septic shock patients; second, a
call for studies in ICU populations other than septic
patients (including trauma patients) was advocated.
Moreover, a placebo is ethically justified because the
placebo is given in addition to standard of care of TBI
patients.
The selection of ICU patients who require hydrocor-
tisone treatment is of particular importance. The con-
cept of CIRCI has recently been introduced to
differentiate the classical chronic corticosteroid insuffi-
ciency (Addison’s disease) from the alteration of the
hypothalamic-pituitary-adrenal axis observed in ICU
patients [29]. CIRCI corresponds to an inadequacy
between the severity of illness and the corticosteroid
activity [19]. The combination of basal cortisolemia
and/or a delta <9 μg/dl provides the best specificity
and sensitivity for the diagnosis of CIRCI associated
with severe sepsis [30]. Finally, recent recommenda-
tions have advocated use of either the basal cortisole-
mia or delta for diagnosis of CIRCI [31]. Regarding
threshold of the basal cortisolemia, our definition is
more liberal (<15 μg/dl) than the consensus statement
(< 10 μg/dl). In the HYPOLYTE study using this lib-
eral definition [10], patients with a normal corticoster-
oid function have a trend toward a decrease in rate of
HAP as compared to patients with corticosteroid insuf-
ficiency treated with placebo (P = .06). Finally, the
Corti-TC trial is not designed to test the accuracy of
the CIRCI definition in trauma patients.
Despite inhibition of the cortisol synthesis, etomidate
is recommended for Rapid Sequence Induction of multi-
ple trauma patients [31]. For single bolus injection, the
duration of adrenal blockade varies from 12 hours [32]
to 24 hours [33], but it should be noted that this block-
ade was inconstantly reported [34]. In the Corti-TC
study, a corticotropin test will not be performed within
the first 8 hours following etomidate infusion and eto-
midate use in ICU is discouraged. Finally, as etomidate
use may impact the results, etomidate will be considered
as an effect modifier for the analysis (sensitivity
analysis).
In conclusion, the Corti-TC trial is a nationwide
investigator-initiated randomized controlled trial pow-
ered to test the hypothesis that the association of hydro-
cortisone with fludrocortisone in severe TBI patients
prevents HAP. The Corti-TC trial also determines the
effects of low dose of corticosteroids on duration of
mechanical ventilation, length of ICU stay, organ failures
and rate of death. An ancillary study will assess the long
term neurological and psychological recovery of the
included patients.
Trial status
On October, the 5th of 2011, 110 patients have been
enrolled in the study. The first interim analysis will be
performed in november 2011, after the collection of the
primary end point of the 110th patient.
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